|[March 05, 2014]
Dr. Reddy's Announces the Launch of Moxifloxacin Hydrochloride Tablets
HYDERABAD, India --(Business Wire)--
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced today that it has
launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic
equivalent generic version of Avelox® (moxifloxacin HCl)
tablets 400 mg in the US market on March 04, 2014, following the
approval by the United States Food & Drug Administration (USFDA).
The Avelox® (moxifloxacin HCl) tablets brand had U.S. sales
of approximately $195 Million for the most recent twelve months ending
in December 2013 according to IMS Health*.
Dr. Reddy's Moxifloxacin Hydrochloride Tablets, 400 mg is available in
bottle counts of 30.
Fluoroquinolones, including moxifloxacin, are
associated with an increased risk of tendinitis and tendon rupture in
all ages. This risk is further increased in older patients usually over
60 years of age, in patients taking corticosteroid drugs, and in
patients with kidney, heart or lung transplants.
Fluoroquinolones, including moxifloxacin, may exacerbate muscle
weakness in persons with myasthenia gravis. Avoid moxifloxacin in
patients with known history of myasthenia gravis.
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses -
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products - Dr. Reddy's offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Major therapeutic focus is
on gastro-intestinal, cardiovascular, diabetology, oncology, pain
management and anti-infective. Major markets include India, USA,
Russia-CIS and Europe apart from other select geographies within
Emerging Markets. For more information, log on to: www.drreddys.com
Avelox® is a registered trademark of Bayer Aktiengesellschaft
and is used under license by Merck Sharp (News - Alert) & Dohme Corp., a subsidiary of
Merck & Co., Inc.
*IMS National Sales Perspectives: Retail and Non-Retail December 2013
[ Back To TMCnet.com's Homepage ]